Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups

Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups

Abstract With the recent FDA approval of tumor mutational burden-high (TMB-H) status as a biomarker for treatment with a PD-1 inhibitor regardless of tumor type, accurate assessment of patient-specific TMB is more critical now more than ever. Using paired tumor and germline exome sequencing data fro...

Full description

Bibliographic Details
Main Authors: Yan W. Asmann, Kaushal Parikh, P. Leif Bergsagel, Haidong Dong, Alex A. Adjei, Mitesh J. Borad, Aaron S. Mansfield
Format: Article
Language:English
Published: Nature Portfolio 2021-03-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-021-00164-5

Internet

https://doi.org/10.1038/s41698-021-00164-5

Similar Items